Skip to main content

Table 2 Pharmacological pattern and cost per cycle

From: Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain

Treatment

Cost/mg **

Dosage/(mg/m 2)†

Days of treatment/cycle

Cost per cycle

AZA REGIMEN

Azacitidine

€3.40/mg

75

7

€3,028.14

LDC REGIMEN

Cytarabine

€0.0271/mg

150

7

€48.38

SDC REGIMEN*

Cytarabine/Idarubicin

   

€965.16

Cytarabine

€0.0271/mg

1000

7

€322.56

Idarubicin

€10.52/mg

12

3

€642.60

Cytarabine/Mitoxantrone

   

€543.55

Cytarabine

€0.0271/mg

1000

7

€322.56

Mitoxantrone

€3.62/mg

12

3

€220.99

Cytarabine/Daunorubicin

   

€377.12

Cytarabine

€0.0271/mg

1000

7

€322.56

Daunorubicin

€0.179/mg

60

3

€54.56

Cytarabine/Idarubicin/Etoposide

   

€848.68

Cytarabine

€0.0271/mg

1000

4

€184.32

Idarubicin

€10.52/mg

12

3

€642.60

Etoposide

€0.043/mg

100

3

€21.76

  1. Abbreviations: AZA = azacitidine; LDC = low dose chemotherapy; SDC = standard dose chemotherapy.
  2. * Data were pooled corresponding to Spanish usual care weight for each treatment (pooled cost: €790. 41). ** All costs are expressed in ex-factory price and are discounted according to RD 15/2010 † Mean body surface was assumed to be 1.7 m2.